Wurm Florian M
Laboratory of Cellular Biotechnology, Institute of Biological Engineering and Biotechnology, Faculty of Life Sciences, Swiss Federal Institute of Technology, 1015 Lausanne, Switzerland. florian@
Nat Biotechnol. 2004 Nov;22(11):1393-8. doi: 10.1038/nbt1026.
Cultivated mammalian cells have become the dominant system for the production of recombinant proteins for clinical applications because of their capacity for proper protein folding, assembly and post-translational modification. Thus, the quality and efficacy of a protein can be superior when expressed in mammalian cells versus other hosts such as bacteria, plants and yeast. Recently, the productivity of mammalian cells cultivated in bioreactors has reached the gram per liter range in a number of cases, a more than 100-fold yield improvement over titers seen for similar processes in the mid-1980s. This increase in volumetric productivity has resulted mainly from improvements in media composition and process control. Opportunities still exist for improving mammalian cell systems through further advancements in production systems as well as through vector and host cell engineering.
由于培养的哺乳动物细胞具有正确进行蛋白质折叠、组装和翻译后修饰的能力，它们已成为生产临床应用重组蛋白的主要系统。因此，与细菌、植物和酵母等其他宿主相比，在哺乳动物细胞中表达的蛋白质质量和功效可能更优。最近，在许多情况下，生物反应器中培养的哺乳动物细胞的生产力已达到每升数克的范围，比20世纪80年代中期类似工艺的滴度提高了100多倍。体积生产力的这种提高主要得益于培养基成分和工艺控制的改进。通过生产系统的进一步发展以及载体和宿主细胞工程，改善哺乳动物细胞系统的机会仍然存在。
